Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.